Home » Sigma-Aldrich Completes Acquisition of Proligo
Sigma-Aldrich Completes Acquisition of Proligo
April 4, 2005
Sigma-Aldrich Corporation announced today that it has completed its acquisition of the Proligo Group (Proligo) from Degussa AG (Frankfurt: DGXG.DE). Terms of the proposed purchase were not disclosed. Proligo, a global supplier of key genomics research tools including custom DNA, custom RNA and phosphoramidite raw materials used for DNA and RNA synthesis, had 2004 sales of approximately $40 million. Nine months of Proligo's operating results will be added to Sigma-Aldrich's performance in 2005, increasing overall sales growth by roughly 2%.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19577920&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct